Patents by Inventor Ronald H. Goldfarb

Ronald H. Goldfarb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-PEGYLATED LIPOSOMAL DOXORUBICIN COMBINATIONS FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
    Publication number: 20150250723
    Abstract: The present invention relates to a method for treating triple-negative metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises nonpegylated liposomal doxorubicin, a taxane and a chemotherapeutic agent selected from the group consisting of capecitabine, vinorelbine, gemcitahine, carboplatin, and ixahepilone, and wherein said individual previously has been administered an anthracycline. In some embodiments, the individual is not administered transtuzumab.
    Type: Application
    Filed: September 5, 2013
    Publication date: September 10, 2015
    Inventors: Marcel Rozencweig, Ronald H. Goldfarb, Salvatore Forenza
  • NON-PEGYLATED LIPOSOMAL DOXORUBICIN TRIPLE COMBINATION THERAPY
    Publication number: 20110256215
    Abstract: The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.
    Type: Application
    Filed: June 29, 2011
    Publication date: October 20, 2011
    Applicant: SOPHERION THERAPEUTICS LLC
    Inventors: Marcel Rozencweig, Ronald H. Goldfarb, Salvatore Forenza
  • Non-pegylated liposomal doxorubicin triple combination therapy
    Patent number: 8026267
    Abstract: The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: September 27, 2011
    Assignee: Sopherion Therapeutics, LLC
    Inventors: Marcel Rozencweig, Ronald H. Goldfarb, Salvatore Forenza
  • NON-PEGYLATED LIPOSOMAL DOXORUBICIN TRIPLE COMBINATION THERAPY
    Publication number: 20100323004
    Abstract: The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.
    Type: Application
    Filed: September 10, 2010
    Publication date: December 23, 2010
    Applicant: SOPHERION THERAPEUTICS LLC
    Inventors: Marcel Rozencweig, Ronald H. Goldfarb, Salvatore Forenza
  • NON-PEGYLATED LIPOSOMAL DOXORUBICIN TRIPLE COMBINATION THERAPY
    Publication number: 20100260831
    Abstract: The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.
    Type: Application
    Filed: April 8, 2010
    Publication date: October 14, 2010
    Inventors: Marcel Rozencweig, Ronald H. Goldfarb, Salvatore Forenza
  • MULTICATALYTIC PROTEASE INHIBITORS FOR USE AS ANTI-TUMOR AGENTS
    Publication number: 20010012854
    Abstract: The present invention relates to methods for the use of specified inhibitors of multicatalytic protease (MCP) for use as inducers of programmed cell death (i.e., apoptosis) in tumor cells, and more particularly as anti-tumor agents. The present invention provides methods for inducing apoptosis in transformed cells, inhibiting proliferation of transformed cells, and inhibiting the growth of tumors using the MCP inhibitors.
    Type: Application
    Filed: December 15, 1998
    Publication date: August 9, 2001
    Inventors: ROBERT SIMAN, JITESH P. JANI, RONALD H. GOLDFARB, QING PING DOU
  • Methods of reducing tumor colony number using novel benzothiazole compounds
    Patent number: 6013659
    Abstract: This invention pertains to methods of treating cancer by reducing tumor colony number in a mammalian host using benzothiazole activated natural killer cells and interleukin-2. The benzothiazoles are of the formula I: ##STR1## wherein R.sub.1 is 4-OMe and R.sub.2 is 4-tBu or 4-CF.sub.3.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: January 11, 2000
    Assignee: University of Pittsburgh
    Inventors: Ronald H. Goldfarb, Masami Ohashi, Kohichiro Yoshino